Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.

Cancer Diagnostics and Risk Assessment

Technology Transfer Contacts

Inna Khartchenko, MS, MBA
Director, Technology Transfer
215-214-3989
Inna.Khartchenko@fccc.edu
Natalia Shalginskikh, PhD
Licensing Associate,
Technology Transfer
267-963-7121
Natalia.Shalginskikh@fccc.edu
Tatiana Venkova, PhD
Licensing Associate,
Technology Transfer
215-983-0257
Tatiana.Venkova@fccc.edu

(technologies available for licensing)

Note: Links to Patents may require a browser newer than Internet Explorer 9, such as Chrome, Safari, Firefox, Edge, or Internet Explorer 11

TECH ID	TITLE	LEAD INVENTOR	CONTACT
07-43	Biomarkers for Early Pancreatic Cancer Detection and Treatment Patent No. US8609437B2; Summary	Anthony Yeung	Inna Khartchenko
256-JT	Novel Diagnostic and Prognostic Marker for Malignant Mesothelioma Patent No. US10344333B2; Summary	Joseph Testa	Tatiana Venkova
305-MC	Estrogen Metabolite Levels and CYP1B1 Polymorphisms in Lung Cancer Diagnosis, Prognosis, and Risk Assessment Published Application No.US20190180877A1	Margie Clapper	Natalia Shalginskikh
312-GE	Novel Diagnostic Method for Predisposition to Colorectal Cancer Patent No. US9157124B2; Summary	Greg Enders	Tatiana Venkova
394-EG	Novel Biomarkers for Prognosis and Diagnosis of Prostate Cancer Published Application No.WO2017049023A1; Summary Patent No. US10724100B2 Other Patent Applications Pending	Erica Golemis	Tatiana Venkova
396-EC	Novel Biomarker For Risk Assessment And Treatment Evaluation For Cancers With Fibrosis Published Application No.WO2018005355; Summary	Edna Cukierman	Natalia Shalginskikh
426-SA	Methods For Diagnosis And Treatment Of Patients Having Solid Tumors Published Application No.US20200232041A1; Summary	Sanjeevani Arora	Tatiana Venkova
431-WE	High EGFR Somatic Mutation Frequency Targeting the TK Domain in Colorectal Cancer Patients with Microsatellite Instability (MSI) Published Application No.WO2018157032A1; Summary	Wafik El-Deiry	Tatiana Venkova
443-JFB	Novel Cancer Prognostic based on MHC-I Genotype and Presentability Published Application No.WO2019005764A1; Summary	Joan Font-Burgada	Tatiana Venkova
461-PA	Urinary DNA Detection for Monitoring of Urothelial Cancer Published Application No.WO2019222325A1; Summary	Philip Abbosh	Natalia Shalginskikh
516-ZY	Applications of exosomes in the diagnosis of brain tumors Published Application No.WO2021216733A2	Zeng-Jie Yang	Natalia Shalginskikh
522-MC	Estrogen Metabolite Levels and EGFR Mutations in Lung Cancer Risk Stratification and Treatment Published Application No.WO2021142408A1	Margie Clapper	Natalia Shalginskikh
534-JR	The usage of r-HCG and the genomic signature of the breast induced by r-HCG in BRCA 1/2 carriers Published Application No.WO2022125417A1; Summary	Jose Russo	Natalia Shalginskikh
546-JT	Malignant Mesothelioma Susceptibility as a Result of Germline Gene Alteration: novel prognostic and diagnostic marker for mesothelioma. Patent pending; Summary	Joseph Testa	Tatiana Venkova